RMC-5127 manufacturers
- RMC-5127
-
-
2026-06-30
- CAS:3056146-38-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000
|
| | RMC-5127 Basic information |
| Product Name: | RMC-5127 | | Synonyms: | RMC-5127;(2S,3S)-N-((64S,3S,4S)-12-(5-(4-Cyclopropylpiperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-11-(2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-11H-8-oxa-62,63-diaza-2(4,2)-thiazola-1(5,3)-indola-6(2,4)-bicyclo[3.1.1]heptanacycloundecaphane-4-yl)-3-methyloxetane-2-carboxamide | | CAS: | 3056146-38-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![RMC-5127 Structure]() |
| | RMC-5127 Chemical Properties |
| | RMC-5127 Usage And Synthesis |
| Description | RMC-5127 is an orally bioavailable, mutant-selective tri-complex inhibitor of the GTP-bound (ON) form of RASG12V. | | Uses | RMC-5127 exhibits CNS penetration and induces robust anti-tumor activity in KRASG12V-mutant NSCLC, PDAC, and CRC xenograft models. | | Mechanism of action | RMC-5127 non-covalently binds cyclophilin A (CypA) to form a binary complex that creates a high-affinity tri-complex with RASG12V(ON), sterically blocking effector binding and potently suppressing RAS signaling. |
| | RMC-5127 Preparation Products And Raw materials |
|